These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 25576353)

  • 21. Carboplatin/pemetrexed/bevacizumab in the treatment of patients with advanced non-small-cell lung cancer: a single-institution experience.
    Malhotra B; Evans T; Weiss J; Eaby B; Stonehouse-Lee S; Sherry V; Langer CJ
    Clin Lung Cancer; 2010 May; 11(3):192-7. PubMed ID: 20439196
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real world study of regimen containing bevacizumab as first-line therapy in Chinese patients with advanced non-small cell lung cancer.
    Xing P; Mu Y; Wang Y; Hao X; Zhu Y; Hu X; Wang H; Liu P; Lin L; Wang Z; Li J
    Thorac Cancer; 2018 Jul; 9(7):805-813. PubMed ID: 29768721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease.
    Shimizu R; Fujimoto D; Kato R; Otoshi T; Kawamura T; Tamai K; Matsumoto T; Nagata K; Otsuka K; Nakagawa A; Otsuka K; Katakami N; Tomii K
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1159-66. PubMed ID: 25245821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Platinum-based doublet chemotherapy plus bevacizumab without bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC).
    Nørøxe DS; Wallerek S; Sørensen JB
    Anticancer Res; 2013 Aug; 33(8):3275-8. PubMed ID: 23898091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064).
    O'Brien ME; Gaafar R; Hasan B; Menis J; Cufer T; Popat S; Woll PJ; Surmont V; Georgoulias V; Montes A; Blackhall F; Hennig I; Schmid-Bindert G; Baas P;
    Eur J Cancer; 2015 Aug; 51(12):1511-28. PubMed ID: 26074395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficacy and Safety of Bevacizumab Combined with Chemotherapy as Second-line or Later-line Treatment in Advanced Nonsquamous Non-small Cell Lung Cancer].
    Zheng X; Wang H; Zhang G; Yan X; Ma Z
    Zhongguo Fei Ai Za Zhi; 2018 Jul; 21(7):513-518. PubMed ID: 30037370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
    Herbst RS; O'Neill VJ; Fehrenbacher L; Belani CP; Bonomi PD; Hart L; Melnyk O; Ramies D; Lin M; Sandler A
    J Clin Oncol; 2007 Oct; 25(30):4743-50. PubMed ID: 17909199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bevacizumab in Combination with Platinum-Based Chemotherapy in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with or without Brain Metastases: A French Cohort Study (EOLE).
    Bennouna J; Falchero L; Schott R; Bonnetain F; Coudert M; Ben Hadj Yahia B; Chouaid C
    Oncology; 2018; 94(1):55-64. PubMed ID: 29065416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089).
    Barlesi F; Scherpereel A; Rittmeyer A; Pazzola A; Ferrer Tur N; Kim JH; Ahn MJ; Aerts JG; Gorbunova V; Vikström A; Wong EK; Perez-Moreno P; Mitchell L; Groen HJ
    J Clin Oncol; 2013 Aug; 31(24):3004-11. PubMed ID: 23835708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial.
    Gridelli C; Bennouna J; de Castro J; Dingemans AM; Griesinger F; Grossi F; Rossi A; Thatcher N; Wong EK; Langer C
    Clin Lung Cancer; 2011 Nov; 12(6):407-11. PubMed ID: 21705281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real world study of the continuation of bevacizumab beyond disease progression after first-line treatment containing bevacizumab in Chinese patients with advanced non-small cell lung cancer.
    Xing P; Mu Y; Wang Y; Hao X; Zhu Y; Hu X; Wang H; Liu P; Lin L; Wang Z; Li J
    Thorac Cancer; 2018 Dec; 9(12):1716-1724. PubMed ID: 30324773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
    Cohen MH; Gootenberg J; Keegan P; Pazdur R
    Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancer.
    Soejima K; Naoki K; Ishioka K; Nakamura M; Nakatani M; Kawada I; Watanabe H; Nakachi I; Yasuda H; Satomi R; Nakayama S; Yoda S; Ikemura S; Terai H; Sato T; Ohgino K; Arai D; Tani T; Kuroda A; Nishino M; Betsuyaku T
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):513-9. PubMed ID: 25563719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
    Patel JD; Hensing TA; Rademaker A; Hart EM; Blum MG; Milton DT; Bonomi PD
    J Clin Oncol; 2009 Jul; 27(20):3284-9. PubMed ID: 19433684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.
    Zhou C; Wu YL; Chen G; Liu X; Zhu Y; Lu S; Feng J; He J; Han B; Wang J; Jiang G; Hu C; Zhang H; Cheng G; Song X; Lu Y; Pan H; Zheng W; Yin AY
    J Clin Oncol; 2015 Jul; 33(19):2197-204. PubMed ID: 26014294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of docetaxel-plus-bevacizumab combination therapy in patients previously treated for advanced non-squamous non-small cell lung cancer.
    Ohyanagi F; Yanagitani N; Kudo K; Kawano Y; Sakatani T; Tanimoto A; Nishizawa H; Horiike A; Hagiwara S; Horai T; Nishio M
    Anticancer Res; 2014 Sep; 34(9):5153-8. PubMed ID: 25202107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer.
    Asahina H; Sekine I; Horinouchi H; Nokihara H; Yamamoto N; Kubota K; Tamura T
    Clin Lung Cancer; 2012 Jan; 13(1):39-43. PubMed ID: 21890422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
    Spigel DR; Burris HA; Greco FA; Shipley DL; Friedman EK; Waterhouse DM; Whorf RC; Mitchell RB; Daniel DB; Zangmeister J; Bass JD; Hainsworth JD
    J Clin Oncol; 2011 Jun; 29(18):2582-9. PubMed ID: 21576636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases.
    Socinski MA; Langer CJ; Huang JE; Kolb MM; Compton P; Wang L; Akerley W
    J Clin Oncol; 2009 Nov; 27(31):5255-61. PubMed ID: 19738122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
    Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS
    Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.